Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients

Denise M. Kay, Dawn Moran, Lina Moses, Parvoneh Poorkaj, Cyrus P. Zabetian, John Nutt, Stewart A. Factor, Chang En Yu, Jennifer S. Montimurro, Robert G. Keefe, Gerard D. Schellenberg, Haydeh Payami

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objective: Homozygous or compound heterozygous parkin mutations cause juvenile parkinsonism. Heterozygous parkin mutations are also found in patients with typical Parkinson's disease (PD), but it is unclear whether a single "mutation" in a patient is related to disease or is coincidental, because the mutation frequency in control subjects is unknown. We present a comprehensive sequence analysis of parkin in control subjects. Methods: A total of 302 patients and 301 control subjects were sequenced, and findings were replicated in 1,260 additional patients and 1,657 control subjects. Results: Thirty-four variants were detected, of which 21 were novel; 12 were polymorphisms and 22 were rare variants. Patients and control subjects did not differ in the frequency, type, or functional location of the variants. Even P437L, a common mutation thought to be pathogenic, was present in unaffected control subjects. Interpretation: parkin point mutations are not exclusive to PD. The mere presence of a single point mutation in a patient, in the absence of a second mutation, should not be taken as a cause of disease unless corroborated by family data and functional studies. This study does not support the notion that heterozygous parkin sequence variants (mutations or polymorphisms) are risk factors for PD. Whether heterozygous dosage anomalies are associated with PD remains to be determined.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalAnnals of Neurology
Volume61
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Point Mutation
Mutation
Parkinson Disease
Parkinsonian Disorders
Mutation Rate
Sequence Analysis

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. / Kay, Denise M.; Moran, Dawn; Moses, Lina; Poorkaj, Parvoneh; Zabetian, Cyrus P.; Nutt, John; Factor, Stewart A.; Yu, Chang En; Montimurro, Jennifer S.; Keefe, Robert G.; Schellenberg, Gerard D.; Payami, Haydeh.

In: Annals of Neurology, Vol. 61, No. 1, 01.2007, p. 47-54.

Research output: Contribution to journalArticle

Kay, DM, Moran, D, Moses, L, Poorkaj, P, Zabetian, CP, Nutt, J, Factor, SA, Yu, CE, Montimurro, JS, Keefe, RG, Schellenberg, GD & Payami, H 2007, 'Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients', Annals of Neurology, vol. 61, no. 1, pp. 47-54. https://doi.org/10.1002/ana.21039
Kay, Denise M. ; Moran, Dawn ; Moses, Lina ; Poorkaj, Parvoneh ; Zabetian, Cyrus P. ; Nutt, John ; Factor, Stewart A. ; Yu, Chang En ; Montimurro, Jennifer S. ; Keefe, Robert G. ; Schellenberg, Gerard D. ; Payami, Haydeh. / Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. In: Annals of Neurology. 2007 ; Vol. 61, No. 1. pp. 47-54.
@article{f262f4e4bee443b9b50c722088df908d,
title = "Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients",
abstract = "Objective: Homozygous or compound heterozygous parkin mutations cause juvenile parkinsonism. Heterozygous parkin mutations are also found in patients with typical Parkinson's disease (PD), but it is unclear whether a single {"}mutation{"} in a patient is related to disease or is coincidental, because the mutation frequency in control subjects is unknown. We present a comprehensive sequence analysis of parkin in control subjects. Methods: A total of 302 patients and 301 control subjects were sequenced, and findings were replicated in 1,260 additional patients and 1,657 control subjects. Results: Thirty-four variants were detected, of which 21 were novel; 12 were polymorphisms and 22 were rare variants. Patients and control subjects did not differ in the frequency, type, or functional location of the variants. Even P437L, a common mutation thought to be pathogenic, was present in unaffected control subjects. Interpretation: parkin point mutations are not exclusive to PD. The mere presence of a single point mutation in a patient, in the absence of a second mutation, should not be taken as a cause of disease unless corroborated by family data and functional studies. This study does not support the notion that heterozygous parkin sequence variants (mutations or polymorphisms) are risk factors for PD. Whether heterozygous dosage anomalies are associated with PD remains to be determined.",
author = "Kay, {Denise M.} and Dawn Moran and Lina Moses and Parvoneh Poorkaj and Zabetian, {Cyrus P.} and John Nutt and Factor, {Stewart A.} and Yu, {Chang En} and Montimurro, {Jennifer S.} and Keefe, {Robert G.} and Schellenberg, {Gerard D.} and Haydeh Payami",
year = "2007",
month = "1",
doi = "10.1002/ana.21039",
language = "English (US)",
volume = "61",
pages = "47--54",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients

AU - Kay, Denise M.

AU - Moran, Dawn

AU - Moses, Lina

AU - Poorkaj, Parvoneh

AU - Zabetian, Cyrus P.

AU - Nutt, John

AU - Factor, Stewart A.

AU - Yu, Chang En

AU - Montimurro, Jennifer S.

AU - Keefe, Robert G.

AU - Schellenberg, Gerard D.

AU - Payami, Haydeh

PY - 2007/1

Y1 - 2007/1

N2 - Objective: Homozygous or compound heterozygous parkin mutations cause juvenile parkinsonism. Heterozygous parkin mutations are also found in patients with typical Parkinson's disease (PD), but it is unclear whether a single "mutation" in a patient is related to disease or is coincidental, because the mutation frequency in control subjects is unknown. We present a comprehensive sequence analysis of parkin in control subjects. Methods: A total of 302 patients and 301 control subjects were sequenced, and findings were replicated in 1,260 additional patients and 1,657 control subjects. Results: Thirty-four variants were detected, of which 21 were novel; 12 were polymorphisms and 22 were rare variants. Patients and control subjects did not differ in the frequency, type, or functional location of the variants. Even P437L, a common mutation thought to be pathogenic, was present in unaffected control subjects. Interpretation: parkin point mutations are not exclusive to PD. The mere presence of a single point mutation in a patient, in the absence of a second mutation, should not be taken as a cause of disease unless corroborated by family data and functional studies. This study does not support the notion that heterozygous parkin sequence variants (mutations or polymorphisms) are risk factors for PD. Whether heterozygous dosage anomalies are associated with PD remains to be determined.

AB - Objective: Homozygous or compound heterozygous parkin mutations cause juvenile parkinsonism. Heterozygous parkin mutations are also found in patients with typical Parkinson's disease (PD), but it is unclear whether a single "mutation" in a patient is related to disease or is coincidental, because the mutation frequency in control subjects is unknown. We present a comprehensive sequence analysis of parkin in control subjects. Methods: A total of 302 patients and 301 control subjects were sequenced, and findings were replicated in 1,260 additional patients and 1,657 control subjects. Results: Thirty-four variants were detected, of which 21 were novel; 12 were polymorphisms and 22 were rare variants. Patients and control subjects did not differ in the frequency, type, or functional location of the variants. Even P437L, a common mutation thought to be pathogenic, was present in unaffected control subjects. Interpretation: parkin point mutations are not exclusive to PD. The mere presence of a single point mutation in a patient, in the absence of a second mutation, should not be taken as a cause of disease unless corroborated by family data and functional studies. This study does not support the notion that heterozygous parkin sequence variants (mutations or polymorphisms) are risk factors for PD. Whether heterozygous dosage anomalies are associated with PD remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=33846833930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846833930&partnerID=8YFLogxK

U2 - 10.1002/ana.21039

DO - 10.1002/ana.21039

M3 - Article

VL - 61

SP - 47

EP - 54

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -